

JC10 Rec'd PCT/PTO 21 MAR 2002

| | | | |
|--|---|---|---|
| Form PTO-1390 (REV. 11-2000) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTORNEY'S DOCKET NUMBER 9013-46 |
| TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371 | | | U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/088807 |
| INTERNATIONAL APPLICATION NO. PCT/GB00/02903 | INTERNATIONAL FILING DATE July 28, 2000 | PRIORITY DATE CLAIMED July 30, 1999 | |
| TITLE OF INVENTION PEPTIDE TRANSPORT | | | |
| APPLICANT(S) FOR DO/EO/US James Duncan MORRISON; Michael Leslie LUCAS; and Sarah WHEELER | | | |
| Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: | | | |
| <ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below. 4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31). 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). <ol style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4) 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application Under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input checked="" type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report Under PCT Article 36 (35 U.S.C. 371(c)(5)). | | | |
| Items 11 to 20 below concern document(s) or information included: | | | |
| <ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. 14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4) 20. <input checked="" type="checkbox"/> Other items or information: Petition for Revival and fee; Request Form; International Search Report; International Preliminary Examination Report | | | |

10/0888807
 JC10 Rec'd PCT/PTO 21 MAR 2002

| | | | | | |
|---|--|--|--------------|-----------------------------|---------|
| U.S. APPLICATION NO. 10/0888807 | | INTERNATIONAL APPLICATION NO. PCT/GB00/02902 | | ATTORNEY DOCKET NO. 9013-46 | |
| 21. <input checked="" type="checkbox"/> The following fees are submitted. BASIC NATIONAL FEE (37 CFR 1.492(a)(1) - (5)) | | | | CALCULATIONS PTO USE ONLY | |
| Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00 | | | | | |
| International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$890.00 | | | | | |
| International preliminary examination fee 37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$740.00 | | | | | |
| International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4). \$710.00 | | | | | |
| International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$100.00 | | | | | |
| ENTER APPROPRIATE BASE FEE AMOUNT = | | | | \$890.00 | |
| Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(c)). | | | | \$ | |
| CLAIMS | | NUMBER FILED | NUMBER EXTRA | RATE | \$ |
| Total claims | | 23 - 20 = | 3 | x \$18.00 | \$54.00 |
| Independent Claims | | 4- 3 = | 1 | x \$84.00 | \$84.00 |
| MULTIPLE DEPENDENT CLAIM(S) (if applicable) | | | | + \$280.00 | \$ |
| TOTAL OF ABOVE CALCULATIONS = | | | | \$1,028.00 | |
| <input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2 | | | | \$514.00 | |
| SUBTOTAL = | | | | \$ | |
| Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)). | | | | \$ | |
| TOTAL NATIONAL FEE = | | | | \$ | |
| Fee for Recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property + | | | | \$ | |
| Petition Fee | | | | \$640.00 | |
| TOTAL FEES ENCLOSED = | | | | \$1,154.00 | |
| | | | | Amount to be refunded: | \$ |
| | | | | charged: | \$ |

- a. ☒ A check in the amount of \$1,154.00 to cover the above fees is enclosed.
- b. ☐ Please charge my Deposit Account No. 50-0220 in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0220. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

[Signature]
 F. Michael Sajovec, Reg. No. 31,793

Date: March 21, 2002



20792

PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EL920741553US

Date of Deposit: March 21, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: BOX PCT, Attn: DO/EO/US, Commissioner for Patents, Washington, DC 20231.

[Signature]
 Lucille H. Gillette

10/088807

IC10 Rec'd PCT/PTO 21 MAR 2002
PATENT

Attorney's Docket No. 9013-46

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

In re: James Duncan Morrison et al.
Serial No. to be assigned
Filed: concurrently herewith
For: **PEPTIDE TRANSPORT**

Date: March 21, 2002

BOX PCT
Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Prior to the examination of the above application, please amend the above-identified application as follows. A "Version with Marking to Show Changes Made" is attached.

IN THE SPECIFICATION:

Please amend the specification as follows:

At page one, following the title "PEPTIDE TRANSPORT," please insert:

-- **Related Applications**

This application claims priority under 35 U.S.C. § 371 from PCT Application No. PCT/GB00/02903, filed in English on July 28, 2000, which claims the benefit of Great Britain Application Serial No. 9917793.3 filed on July 30, 1999, the disclosures of which are incorporated by reference herein in their entireties.--

IN THE CLAIMS:

Please amend Claims 3, 5-8, 12, 15, 18-20, and 23 as follows:

3. (Amended) The amide according to claim 1 wherein the peptide is from 4 to 600 amino acids long.

In re: James Duncan Morrison et al.
Serial No. to be assigned
Filed: concurrently herewith
Page 2

5. (Amended) The amide according to claim 1 wherein the bile salt is mono-, di- or tri-hydroxylated.

6. (Amended) The amide according to claim 1 wherein the bile salt contains a 3 α -hydroxyl group.

7. (Amended) The amide according to claim 1 wherein the bile salt is an amphiphilic polyhydric sterol bearing carboxyl groups as part of the primary side chain.

8. (Amended) The amide according to claim 1 wherein the bile salt is underivatised or derivatised.

12. (Amended) An amide according to claim 1 wherein the peptide is selected from insulin, secretin, gastrin, gastrin releasing peptide, glucagon, cholecystokinin (CCK), gastric inhibitory peptide (also known as glucose insulinotropic peptide (GIP)), parathyroid hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone (also known as lutenizing hormone releasing hormone (LHRH)), corticotropin-releasing hormone, somatostatin, adrencorticotropic hormone (ACTH), renin, angiotensin I, angiotensin II, atrial natriuretic hormone (ANH), somatomedins, calcitonin, haemoglobin, cytochrome C, horseradish peroxidase, aprotinin, muchroom tyrosinase, erythropoietin, somatotropin (growth hormone), growth hormone releasing hormone, galanin, urokinase, Factor IX (also known as Christmas factor), tissue plasminogen activator, antibodies superoxide dismutase, catalase, peroxidase, ferritin, interferon, Factor VIII, soy bean trypsin inhibitor, GLP1, blood coagulation factors, somatostatin, antidiuretic hormone (ADH), oxytocin, polysaccharides, hirudin, and glycoproteins, such as follicle stimulating hormone (FSH), lutenizing hormone (LH) inhibin, chorionic gonadotropin (CGT) and thyroid stimulating hormone (TSH), and analogues and fragments of all these, or mixtures of one or more of these.

In re: James Duncan Morrison et al.
Serial No. to be assigned
Filed: concurrently herewith
Page 3

15. (Amended) A pharmaceutical formulation, comprising an amide according to claim 1 and a pharmaceutically acceptable carrier.

18. (Amended) An amide according to claim 1 or a physiologically functional derivative thereof, for use in therapy.

19. (Amended) A method for the preparation of a pharmaceutical formulation comprising bringing into association an amide according to claim 1 and a pharmaceutically acceptable carrier thereof.

20. (Amended) Use of an amide according to claim 1 in the manufacture of a medicament in a form suitable for oral administration.


23. (Amended) Use according to claim 1 wherein said pharmaceutical agent is selected from polypeptides and glycoproteins, polysaccharides, oligonucleotides/polynucleotides, anaesthetics, anxiolytics, hypotics, neuroleptics, anti-depressants, anti-epileptics, anti-Parkinsonian drugs, opioid analgesics, neuropeptide transmitters, neuropeptide transmitter antagonists, muscarinic agonists, anti-cholinesterases, muscarinic antagonists, nicotinic antagonists, direct sympathomimetics, indirect sympathomimetics, adrenergic blocking drugs, adrenoceptor antagonists, vasodilators, anti-angina drugs, cardiotonic drugs, anti-dysrhythmic drugs, anti-coagulants, plasma lipid lowering drugs, anti-anaemia drugs, anti-inflammatory drugs, diuretics, histamine antagonists, anti-peptic ulcer drugs, anti-gut motility disorder drugs, chemotherapy drugs, anti-bacterial drugs, anti-viral drugs, anti-fungal drugs and anti-parasite drugs.

In re: James Duncan Morrison et al.
Serial No. to be assigned
Filed: concurrently herewith
Page 4

REMARKS

The above amendment to the specification has been made to claim priority to the identified PCT and British patent applications. The above claims have been amended to better conform to U.S. practice. Applicants respectfully request substantive examination on the merits.

Respectfully submitted,


E. Michael Sajovec
Registration No. 31,793



20792


PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EL920741553US

Date of Deposit: March 21, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: BOX PCT, Attn: DO/EO/US, Commissioner for Patents, Washington, DC 20231.


Lucille H. Gillette

In re: James Duncan Morrison et al.
Serial No. to be assigned
Filed: concurrently herewith
Page 5

"Version with Marking to Show Changes Made"

3. (Amended) The amide according to **[either of claims 1 or 2]** claim 1 wherein the peptide is from 4 to 600 amino acids long.

5. (Amended) The amide according to **[any preceding]** claim 1 wherein the bile salt is mono-, di- or tri-hydroxylated.

6. (Amended) The amide according to **[any preceding]** claim 1 wherein the bile salt contains a 3 α -hydroxyl group.

7. (Amended) The amide according to **[any previous]** claim 1 wherein the bile salt is an amphiphilic polyhydric sterol bearing carboxyl groups as part of the primary side chain.

8. (Amended) The amide according to **[any previous]** claim 1 wherein the bile salt is underivatized or derivatized.

12. (Amended) An amide according to **[any previous]** claim 1 wherein the peptide is selected from insulin, secretin, gastrin, gastrin releasing peptide, glucagon, cholecystokinin (CCK) gastric inhibitory peptide (also known as glucose insulinotropic peptide (GIP)), parathyroid hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone (also known as luteinizing hormone releasing hormone (LHRH)), corticotropin-releasing hormone, somatostatin, adrenocorticotrophic hormone (ACTH), renin, angiotensin I, angiotensin II, atrial natriuretic hormone (ANH), somatomedins, calcitonin, haemoglobin, cytochrome C, horseradish peroxidase, aprotinin, mushroom tyrosinase, erythropoietin, somatotropin (growth hormone), growth hormone releasing hormone, galanin, urokinase, Factor IX (also known as Christmas factor), tissue plasminogen activator, antibodies superoxide dismutase, catalase, peroxidase, ferritin, interferon, Factor VIII, soy bean trypsin inhibitor, GLP1, blood coagulation factors, somatostatin, antidiuretic hormone (ADH),

In re: James Duncan Morrison et al.
Serial No. to be assigned
Filed: concurrently herewith
Page 6

oxytocin, polysaccharides, hirudin, and glycoproteins, such as follicle stimulating hormone (FSH), lutenizing hormone (LH) inhibin, chorionic gonadotropin (CGT) and thyroid stimulating hormone (TSH), and analogues and fragments of all these, or mixtures of one or more of these.

15. (Amended) A pharmaceutical formulation, comprising an amide according to **[any preceding]** claim 1 and a pharmaceutically acceptable carrier.

18. (Amended) An amide according to **[any one of claims 1-14]** claim 1 or a physiologically functional derivative thereof, for use in therapy.

19. (Amended) A method for the preparation of a pharmaceutical formulation comprising bringing into association an amide according to **[any one of claims 1-14]** claim 1 and a pharmaceutically acceptable carrier thereof.

20. (Amended) Use of an amide according to **[any one of claims 1-14]** claim 1 in the manufacture of a medicament in a form suitable for oral administration.

23. (Amended) Use according to **[to claim 21 or]** claim 1 wherein said pharmaceutical agent is selected from polypeptides and glycoproteins, polysaccharides, oligonucleotides/polynucleotides, anaesthetics, anxiolytics, hypotics, neuroleptics, anti-depressants, anti-epileptics, anti-Parkinsonian drugs, opioid analgesics, neuropeptide transmitters, neuropeptide transmitter antagonists, muscarinic agonists, anti-cholinesterases, muscarinic antagonists, nicotinic antagonists, direct sympathomimetics, indirect sympathomimetics, adrenergic blocking drugs, adrenoceptor antagonists, vasodilators, anti-angina drugs, cardiotonic drugs, anti-dysrhythmic drugs, anti-coagulants, plasma lipid lowering drugs, anti-anaemia drugs, anti-inflammatory drugs, diuretics, histamine antagonists, anti-peptic ulcer drugs, anti-gut motility disorder drugs, chemotherapy drugs, anti-bacterial drugs, anti-viral drugs, anti-fungal drugs and anti-parasite drugs.

PEPTIDE TRANSPORT

The present invention relates to improving and/or increasing the bioavailability of a biologically active substance, such as a peptide. In particular the present invention relates to the conjugation of the biologically active substance to a bile acid. The conjugated biologically active substance is suitable particularly for oral or parenteral administration.

Of all the routes of administration utilised by medicine, oral ingestion is commonly believed to be the most preferred. Such a route of administration, which may be by means of syrup, elixir, tablets, capsules, granules, powders or any other convenient formulation, is generally simple and straightforward and is frequently the least inconvenient or unpleasant route of administration from the patients' point of view.

However, most biologically active materials are very poorly absorbed when administered orally. This is a result of the acidic and hydrolytic environments of the stomach and small intestine, which are hostile to many materials, including proteins, and the intestinal epithelium which acts as a potential barrier to the passage of biologically active materials.

It is possible to provide enteric coated formulations which are protected from the acid environment of the stomach and which allow the biologically active material to survive its passage through the stomach and to be taken up by the body in the small intestine. However, relatively

large molecules such as peptides and proteins are poorly absorbed by the small intestine.

As a result, proteinaceous medicaments, such as insulin which is used to treat diabetes mellitus, have to be taken parenterally, often by subcutaneous, intramuscular or intravenous injection, with all the inconvenience, discomfort and difficulties of patient compliance that this entails.

Besides diabetes mellitus, there are numerous other conditions which require treatment by administration of a proteinaceous compound or another macromolecule. Osteoporosis is a further example of a condition which can be treated with a protein, in this case calcitonin. Another example is dwarfism which is treated with the administration of protein growth hormones.

It has been found that when pharmaceutically-active compounds are administered together with certain bile acids together with a buffer, the bioavailability is increased (WO 96/06635). Where the biologically active material is associated with but not conjugated to a bile acid, it is believed that the bile acid improves absorption of biologically active materials as a result of their action on the cell membranes of epithelial cells.

US 5,641,767 discloses the use of covalently modified bile acids which are suitable for oral administration. However, the modified bile acids themselves are employed as active pharmaceutical agents.

US 5,646,272 describes a bile acid derivative having an active compound bound directly to the bile acid ring system via a bonding member. The bile acid has been shown to assist in the uptake of the active material.

5 Kramer et al (J. Biol. Chem (1994) 269 pp 10621 - 10627) describes how the attachment of a peptide to the C3 position of the bile acid increases uptake of the peptide.

10 Additionally Stephan et al (Biochem. Pharmacol. (1992), 43 pp 1969 - 1974) describes how the conjugation of thyroid hormone (L-T₃) to the carboxy group of cholic acid assists the uptake of the hormone. However, this document teaches the use of conjugated bile acid to target the hormone predominantly to the liver in order to minimise access to non-hepatic cells and thus reduce undesirable side effects.

15 The present invention is based on the unexpected discovery that conjugation of a pharmaceutically active substance to a bile acid via the carboxylic acid group of the bile acid results in improved uptake of the active substance into the blood stream when administered orally.

20 Moreover, it has also been observed that such conjugated material may be administered parenterally at much lower doses than the unconjugated form of the biologically active substance.


25 In a first aspect the present invention provides an amide of a bile acid/salt, wherein the group bound to the bile acid/salt by the amide bond is a peptide of formula (I):



wherein X is at least one polypeptide chain of at least 4 amino acids in length which may be linear, branched or comprise two or more cross-linked polypeptide chains; and

Y is OH, NH₂, or a C₁-C₆ ester group bonded to the terminal carboxy of the polypeptide chain.

In a further aspect the present invention provides an amide of a bile acid/salt of formula (II):



(II)

wherein R¹ to R⁵ are independently selected from OH, H or C₁₋₆ alkyl; and

A is -R⁶-CO-X-Y

wherein R⁶ is C₂ to C₆ branched or linear alkylene;

X is at least one polypeptide chain of at least 4 amino acids in length which may be linear, branched or comprise two or more cross-linked polypeptide chains; and

Y is is OH, NH₂, or a C₁-C₆ ester group bonded to the terminal carboxy of the polypeptide chain.

In the present invention it should be understood that the terms bile salt and bile acid are used interchangeably since the pH of the surrounding environment will determine whether the salt or its acid is present.

5 The peptide is conjugated to the bile salt by means of an amide bond. This amide bond may be formed by covalently bonding to the carboxy group of the bile salt either an α amine or α -imine group or any other amine or imine group belonging to the side chains of the amino acids of the peptide. Such amino and imino acids having an amine group
10 on a side chain include proline, tryptophan, lysine, arginine, histidine, asparagine, glutamine, or any other suitable synthetic or natural amino or imino acid. Therefore, it will be appreciated that more than one bile salt may be conjugated to the one polypeptide chain or
15 protein which may result in a greater uptake of conjugated bile salt-peptide.

Furthermore, these amino or imino groups may be either located at the beginning of the peptide chain or may be located in the interior of the polypeptide chain.

20 Typically the peptide is at least 4 amino acids long. More typically, the peptide is from 4 to 600 amino acids long, such as 4 to 200 amino acids long. The term "peptide" therefore encompasses polypeptides and proteins. Furthermore, peptides modified by, for example,
25 glycosylation, can also be utilised in the present invention, as can a protein comprising two or more polypeptide chains each of length of 4 to 600 amino acids

primary side chain has a carboxyl group which is substituted. Often the substituent will be an amino acid derivative which is linked via its nitrogen atom to the carboxyl group of the bile salt. Derivatised bile salts which may be employed include taurocholate, taurodeoxycholate, taurooursodeoxycholate, taurochenodeoxycholate, glycholate, glycodeoxycholate, glycoursodeoxycholate, glycochenodeoxycholate, tauroolithocholate and glycolithocholate.

It is to be understood that derivatised bile salts may be employed in the present invention by either underivatising and conjugating the peptide to the bile salt or by conjugating the peptide to the amino acid derivative on the derivatised bile salt.

Examples of particular polypeptides or proteins which may be employed in the present invention include insulin, secretin, gastrin, gastrin releasing peptide, glucagon, cholecystokinin (CCK) gastric inhibitory peptide (also known as glucose insulinotropic peptide (GIP)), parathyroid hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone (also known as lutenizing hormone-releasing hormone (LHRH)), corticotropin-releasing hormone, somatostatin, adrencorticotropic hormone (ACTH), renin, angiotensin I, angiotensin II, atrial natriuretic hormone (ANH), somatomedins such as insulin-like growth factors IGF1 and IGF2, calcitonin, haemoglobin, cytochrome C, horseradish peroxidase, aprotinin, mushroom tyrosinase, erythropoietin, somatotropin (growth hormone), growth

hormone releasing hormone, galanin, urokinase, Factor IX (also known as Christmas factor), tissue plasminogen activator, antibodies such as IgG, IgM, IgA, IgD and IgE, superoxide dismutase, catalase, peroxidase, ferritin, interferon, Factor VIII, soy bean trypsin inhibitor, GLP1, other blood coagulation factors, somatostatin, antidiuretic hormone (ADH), oxytocin, polysaccharides, hirudin, and glycoproteins, such as follicle stimulating hormone (FSH), lutenizing hormone (LH), inhibin, chorionic gonadotropin (CGT) and thyroid stimulating hormone (TSH), and analogues and fragments of all of these and all of which can be from any suitable source.

Furthermore, mixtures of one or more of these or any proteins may be employed in the present invention.

Whilst it is possible for the active conjugated peptide to be administered alone, it is preferable to present the active conjugated peptide in a pharmaceutical formulation. Thus in a further aspect, the present invention provides a pharmaceutical formulation, comprising a conjugated peptide according to the present invention and a pharmaceutically acceptable carrier.

Formulations of the present invention, for medical use, comprise a conjugated peptide together with one or more pharmaceutically acceptable carriers and optionally other therapeutic ingredients. The carrier(s) should be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the formulation and substantially non-deleterious to the recipient thereof.

The amount of conjugated peptide required to be effective will, of course, vary and is ultimately at the discretion of the medical or veterinary practitioner. The factors to be considered include the condition being treated, the route of administration, and nature of the formulation, the mammal's body weight, surface area, age and general condition and the particular compound to be administered. A suitable effective dose of compounds of the invention generally lies in the range of about 0.01 to about 120mg/kg bodyweight, e.g. 0.1 to about 120mg/kg body weight, preferably in the range of about 0.1 to 50mg/kg, for example 0.5 to 50mg/kg. The total daily dose may be given as a single dose, multiple doses, e.g. two to six times applications per day. For example, for a 75kg mammal (e.g. a human) the dose range would be about 8 to 9000 mg per day, and a typical dose could be about 50mg per day. If discrete multiple doses are indicated treatment might

typically be 15mg of a compound of Formula (I) given up to 4 times per day.

There is also provided a method for the preparation of a pharmaceutical formulation comprising bringing into association a conjugated peptide of the present invention, and a pharmaceutically acceptable carrier therefor.

Formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, sachets, tablets, lozenges, comprising the active ingredient in a flavoured base, usually sucrose and acacia or tragacanth; or pastilles comprising the active ingredient in an inert base such as gelatin and glycerin, or sucrose and acacia. Each formulation generally contains a predetermined amount of the active compound; as a powder or granules; or a solution or suspension in an aqueous or non-aqueous liquid such as a syrup, an elixir, an emulsion or draught and the like.

A tablet may be made by compression or moulding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active compound in a free-flowing form such as a powder or granules, optionally mixed with a binder, (e.g. povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g. sodium starch glycollate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose), surface active or dispersing agent. Moulded tablets may be made by moulding in a suitable machine a mixture of the

powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropylmethylcellulose in varying proportions to provide the desired release profile.

A syrup may be made by adding the active compound to a concentrated, aqueous solution of a sugar, for example sucrose, to which may also be added any necessary ingredients. Such accessory ingredient(s) may include flavourings, an agent to retard crystallization of the sugar or an agent to increase the solubility of any other ingredients, such as a polyhydric alcohol, for example glycerol or sorbitol.

In addition to the aforementioned ingredients, the formulations of this invention may further include one or more accessory ingredient(s) selected from diluents, buffers, flavouring agents, binders, surface active agents, thickeners, lubricants, preservatives (including antioxidants) and the like.

In a further aspect the present invention provides the use of a conjugated peptide of the present invention in the manufacture of a medicament in a form suitable for oral administration.

In yet a further aspect, the present invention provides the use of a conjugated peptide of the present invention in association with unconjugated peptide.


WO 01/09163

PCT/GB00/02903

12

As mentioned above it has also been found that conjugation of a biologically active material such as a peptide to a bile salt or acid allows lower doses of the biologically active material to be administered parenterally. That is, the pharmacokinetics and/or bioavailability of a biologically active material are improved when a bile salt or acid conjugated biologically active material is added parenterally.

Thus, in a further aspect, the present invention provides use of a compound according to Formula (III):



(III)

wherein R^1 to R^5 are independently selected from OH, H or C_{1-6} alkyl; and

B is $-R^6-CO-Z$

wherein R^6 is C_2 to C_6 branched or linear alkylene; and

Z is a pharmaceutically active agent;

in the manufacture of a medicament suitable for parenteral administration.

The term "pharmaceutically active agent" used herein is defined as any substance, natural or synthetic, which has a physiological action on a living body.

Typically, Z may be bound to the bile acid/salt by an amide linkage.

5 Examples of suitable pharmaceutical agents include polypeptides and glycoproteins, as described herein above as well as polysaccharides, such as heparin, oligonucleotides/polynucleotides and analogues which may be useful in interfering with replication of nucleic acids in
10 virally infected or cancerous cells and for correcting other forms of inappropriate cell proliferation, or as a means of delivery of a sequence of nucleotides for the purpose of enhancing the synthesis of natural compounds otherwise deficit in the body to compensate for that
15 deficiency. Other suitable pharmaceutical agents include anaesthetics such as thiopentone, anxiolytics such as diazepam, hypnotics such as temazepam, neuroleptics such as chlorpromazine, anti-depressants such as amitriptyline, anti-epileptics such as clonazepam, anti-Parkinsonian drugs
20 such as apomorphine, opioid analgesics such as endorphins, dynorphins and enkephalins, neuropeptide transmitters such as vasoactive intestinal polypeptide (VIP), neuropeptide transmitter antagonists such as [Lys¹, Pro²⁵, Arg^{3,4}, Tyr⁶]-VIP, muscarinic agonists such as pilocarpine, anti-
25 cholinesterases such as neostigmine, muscarinic antagonists such as cyclopentolate, nicotinic antagonists such as suxamethonium, direct sympathomimetics such as oxymetazdine

Figure 2 is a graph depicting the effect of intravenous tetragastrin (G4) ($12.5\mu\text{g kg}^{-1}$, first and third arrows), and ileally-infused G4 ($2500\mu\text{g kg}^{-1}$ in 1.0ml saline, second arrow) on gastric secretion in $\mu\text{mol } 15\text{min}^{-1}$ in an anaesthetised rat;

Figure 3 is a graph depicting the effect of intravenous cholate conjugated tetrapeptide (G4-CA) ($15\mu\text{g kg}^{-1}$, first and third arrow), and ileally-infused G4-CA ($600\mu\text{g kg}^{-1}$, second arrow) on gastric acid secretion in $\mu\text{mol } 15\text{min}^{-1}$ in an anaesthetised rat;

5 Figure 4 is a graph depicting the effect of intravenous injection of G4-CA ($15\mu\text{g kg}^{-1}$, first arrow), jejunal infusion of G4-CA ($600\mu\text{g kg}^{-1}$ in 1.0ml, second arrow) and ileal infusion of G4-CA ($600\mu\text{g kg}^{-1}$ in 1.0ml, third arrow) on gastric acid secretion in $\mu\text{mol } 15\text{min}^{-1}$ in an anaesthetised rat;

10 Figure 5 is a graph depicting the effect of intravenous cholate conjugated decapeptide (G10-CA) ($3.3\mu\text{g kg}^{-1}$, first and third arrows), and ileally-infused G10-CA ($1000\mu\text{g kg}^{-1}$ in 1.0ml, second arrow) on gastric acid secretion in an anaesthetised rat;

15 Figure 6 is a graph depicting the effect of intravenous cholate conjugated 34 mer-gastrin (G34-CA) (14ng kg^{-1} , first and third arrows), and ileally-infused G34-CA ($2700\mu\text{g kg}^{-1}$ in 1.0ml, second arrow) on gastric acid secretion in an anaesthetised rat; and

20 Figure 7 is a graph depicting the effect of intravenous cholate conjugated 34 mer-gastrin (G134-CA) (14ng kg^{-1} , first arrow), ileally-infused G34-CA ($2700\mu\text{g kg}^{-1}$ in 1.0 ml, second arrow) and ileally infused G34 ($5250\mu\text{g kg}^{-1}$ in 1.0 ml, third arrow) on gastric acid secretion in an anaesthetised rat.

EXAMPLE 1 - PHYSIOLOGICAL EXPERIMENTS IN VIVO

Experiments were carried out on male Wistar rats of 250-350g, which had been starved overnight, and which were anaesthetized with an I.P. injection of Sagatal (pentobarbitone sodium, obtainable from Rhône Mérieux, Harlow Essex, UK) of dosage appropriate to the body weight. The criterion for anaesthesia was abolition of the hind limb flexor withdrawal reflex. The following surgical procedures were then carried out: tracheostomy to allow artificial ventilation if required, cannulation of the carotid artery to monitor blood pressure, cannulation of the external jugular vein to allow for the slow bolus infusion of drugs, intubation of the stomach at the pyloro-duodenal junction after ligation of the oesophagus to measure gastric acid secretion, cannulation of the terminal ileum and/or of the proximal jejunum distal to the ligament of Treitz for infusion of peptide hormones.

Gastric acid secretion was measured by the following method. 1.0ml of glycine/mannitol buffer (1 part glycine (0.3M) and 4 parts D-mannitol (0.3M) adjusted to pH 6.5) was instilled into the stomach and left for 15 min when withdrawal was made. The HCl secreted was determined by back titration with 10mM NaOH to pH 6.5.

The following test substances were used: Gastrin tetrapeptide (G4) (Trp-Met-Asp-Phe amide (Sigma Chemical Co. T-6515), cholate-Trp-Met-Asp-Phe amide conjugate (G4-CA), gastrin decapeptide (G10) (H-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-amide), cholate-Glu-Glu-Glu-Ala-Tyr-Gly-

Trp-Met-Asp-Phe-amide (G10-CA), 34 mer-gastrin (pGlu-Leu-Gly-Pro-Gln-Gly-Pro-Gln-His-Phe-Ile-Ala-Asp-Leu-Ser-Lys-Lys-Gln-Arg-Pro-Pro-Met-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH₂) and cholate-Glu-Leu-Gly-Pro-Gln-Gly-Pro-Gln-His-Phe-Ile-Ala-Asp-Leu-Ser-Lys-Lys-Gln-Arg-Pro-Pro-Met-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH₂ (G34-CA) the latter five being synthesised *de novo* using Pioneer Peptide Synthesis System, PerSeptive Biosystems. For cholate-conjugated peptides, the final stage involved coupling of the terminal carboxyl group of cholic acid with the amine group of last amino acid in the peptide sequence (see Figure 1). The method which is described in the Pioneer Peptide Synthesis User's Guide will be known to those skilled in the art of peptide synthesis.

The composition and purity of the sample was confirmed with mass spectrometry and HPLC.

RESULTS

The data are expressed as the mean \pm S.D. μ mol HCl secreted by the stomach over the stated time period in response to the experimental procedure.

Experiments with gastrin tetrapeptide (G4)

It was first confirmed that biologically active G4 was not absorbed across the wall of the small intestine as illustrated by a typical experiment in Figure 2.

In 6 experiments, ileal infusion of a large dose of G4 (2500 μ g kg⁻¹ in 1.0ml isotonic saline) actually resulted in

a fall in the mean gastric acid level of $0.23 \pm 0.21 \mu\text{mol hr}^{-1}$ which was significant ($P=0.043$). In response to intravenous injections at the start and end of the experiment, gastric acid secretion increased significantly with respect to baseline by $0.42 \pm 0.10 \mu\text{mol } 15\text{min}^{-1}$ ($P=0.001$) for the first injection and by $0.50 \pm 0.14 \mu\text{mol } 15\text{min}^{-1}$ ($P=0.001$) in response to the second injection: these confirmed the responsiveness and continued viability of the preparation. Thus, it was demonstrated that G4 was not absorbed across the wall of the ileum. In another series of experiments, this lack of absorption of G4 was also confirmed for the upper jejunum.

The key experiment was to test whether G4-CA was absorbed from the small intestine: in this case, the relatively low dose of $600 \mu\text{g kg}^{-1}$ G4-CA was injected intraleally. However, first, it was necessary to confirm that G4-CA had normal biological activity when injected intravenously. The first intravenous injection of G4-CA ($15 \mu\text{g kg}^{-1}$) caused a significant mean peak increase above baseline in total acidity of $0.64 \pm 0.26 \mu\text{mol } 15\text{min}^{-1}$ ($P=0.017$), while the second I.V. injection also caused a significant increase of $0.72 \pm 0.26 \mu\text{mol } 15\text{min}^{-1}$ ($P=0.003$). A typical result is shown in Figure 3.

In a total of 17 rats, ileal administration of G4-CA ($600 \mu\text{g kg}^{-1}$) resulted in a significant mean increase in gastric acid secretion of $1.84 \pm 1.49 \mu\text{mol}$ ($P=0.045$) over the 3hr collection period, as illustrated by Figure 3.

When a solution of tetragastrin and glycocholic acid was added (used in place of cholic acid which by itself is essentially insoluble) so that the ratio of peptide: bile acid in solution was the same as that of the ileally-infused conjugate (approx. 3:2 ratio by weight), the mean response in 5 rats was to cause a drop in mean gastric acid secretion of $0.12 \pm 0.22 \mu\text{mol } 180\text{min}^{-1}$, which was not significantly different from baseline levels ($P=0.28$).

When the G4-CA was infused into the jejunum, no increase in gastric acid secretion occurred, as shown by the typical experiment in Figure 4. Furthermore, when this jejunal infusion was then followed after 3hr by ileal infusion of G4-CA, gastric acid secretion was strongly stimulated.

In 5 rats, infusion of G4-CA ($600 \mu\text{g kg}^{-1}$ in 1.0ml) into the jejunum caused a significant mean reduction in gastric acid levels of $0.70 \pm 0.41 \mu\text{mol } 180\text{min}^{-1}$ ($P=0.018$). By contrast, when G4-CA ($600 \mu\text{g kg}^{-1}$) was subsequently injected intra-ileally (third arrow), the gastric acid levels were significantly increased by $1.63 \pm 0.31 \mu\text{mol}$ ($P=0.001$).

These results demonstrate the absorption of G4-CA with biological activity preserved. The effect required active conjugation of cholic acid to the tetrapeptide since an effect was not present with either tetragastrin alone or with the separate components of the conjugate. Furthermore, the absorption did not occur from the jejunum but was specific to the ileum: this indicates a requirement for bile salt facilitated transport.

Experiments with gastrin decapeptide (G10)

The action of G10 on gastric acid secretion when injected I.V. in the same molar dose as G4 ($36\mu\text{g kg}^{-1}$) in 5 rats was to cause a significant stimulation of the peak gastric acid secretion by $1.28 \pm 0.93\mu\text{mol}$ ($P=0.036$) in response to the initial injection and by $1.45 \pm 1.15\mu\text{mol}$ ($P=0.048$) in response to the second injection at the end of the experiment. Infusion of a large dose of G10 ($6600\mu\text{g kg}^{-1}$ in 1.0ml) into the ileum did not significantly affect gastric acid secretion ($-1.22 \pm 1.93\mu\text{mol 180min}^{-1}$, $P=0.23$). The experimental data were similar to those shown in Figure 2.

By contrast, G10-CA proved to cause responses showing several differences from G10. In 5 rats the following results were obtained. First, G10-CA I.V. was biologically much more active than G10. Even after reduction of the dose to $3.3\mu\text{g kg}^{-1}$ a marked stimulation of gastric acid secretion resulted as shown by significant increases in the mean peak responses: $5.69 \pm 1.46\mu\text{mol}$ ($P=0.001$) in response to the first injection and $7.32 \pm 2.69\mu\text{mol}$ ($P=0.004$) in response to the second injection. This implies that conjugation of G10 to cholate improves bioavailability and activity of G10 when administered intravenously, and is illustrated in the typical result in Figure 5.

When G10-CA was infused intra-ileally on the same molar basis as G4-CA ($1000\mu\text{g kg}^{-1}$ in 1.0ml), there was considerable stimulation of gastric acid secretion with a

G34-CA, injected intravenously on an equimolar basis (14 ng kg^{-1}), caused significantly greater responses than G34 ($P < 0.0036$). In response to the first I.V. injection, the mean peak response was $0.254 \pm 0.023 \text{ } \mu\text{mol}$ ($P = 0.0001$) and in response to the second I.V. injection was $0.400 \pm 0.047 \text{ } \mu\text{mol}$ ($P = 0.0001$). This is illustrated in the typical result in Figure 6. When G34-CA was infused intra-ileally ($2700 \mu\text{g kg}^{-1}$ in 1.0 ml), stimulation of gastric acid secretion occurred with a mean increase of $1.742 \pm 0.277 \mu\text{mol } 180 \text{ min}^{-1}$ ($P = 0.0001$). This confirms that a molecule as large as 34-mer gastrin is transportable across the wall of the small intestine.

Additional Observation

In the prior art, the absorption of peptide hormones or polysaccharides has been described by the mixing of the peptide hormone or polysaccharide with other transport enhancing substances, including bile salts (WO 96/06635 and US 5,866,536). Such a facilitatory action has also been observed with the cholate conjugated derivatives of the present invention. After introduction of the cholate conjugated form of gastrin (G4-CA, G10-CA, G34-CA) into the ileum, absorption of the conjugated gastrin across the ileal wall into the circulation occurred (Figures 3, 5 and 6). When this was followed by ileal instillation of the unconjugated form of gastrin (G4, G10, G34, respectively), absorption of the unconjugated gastrin occurred with a resultant stimulation of gastric acid secretion, whereas injection of the unconjugated gastrin without prior injection of the respective conjugate was without effect on gastric acid secretion (Figure 2). In 4 rats, intraileal infusion of G34 subsequent to intraileal infusion of G34-CA caused a mean increase in gastric acid secretion of $5.68 \pm 1.38 \mu\text{mol } 180 \text{ min}^{-1}$ ($P=0.004$). This is illustrated in Figure 7, which shows the result for G34 but which is also representative of G4 and G10.


CLAIMS

1. An amide of a bile acid/salt, wherein the group bound to the bile acid/salt by the amide bond is a peptide of formula (I):



wherein X is at least one peptide chain of at least 4 amino acids in length which may be linear, branched or comprise two or more cross-linked polypeptide chains; and Y is OH, NH₂, or a C₁-C₆, ester group bonded to the terminal carboxy of the polypeptide chain.

2. An amide of a bile acid/salt of formula (II):



wherein R¹ to R⁵ are independently selected from OH, H or C₁₋₆ alkyl; and

A is -R⁶-CO-X-Y

wherein R⁶ is C₂ to C₆ branched or linear alkylene; X is at least one peptide chain of at least 4 amino acids in length which may be linear, branched or comprise two or more cross-linked polypeptide chains; and Y is OH, NH₂, or a C₁-C₆ ester group bonded to the terminal carboxy of the polypeptide chain.

3. The amide according to either of claims 1 or 2 wherein the peptide is from 4 to 600 amino acids long.

4. The amide according to claim 3 wherein the peptide is from 4 to 200 amino acids long.

5. The amide according to any preceding claim wherein the bile salt is mono-, di- or tri-hydroxylated.

6. The amide according to any preceding claim wherein the bile salt contains a 3 α -hydroxyl group.

7. The amide according to any previous claim wherein the bile salt is an amphiphilic polyhydric sterol bearing carboxyl groups as part of the primary side chain.

8. The amide according to any previous claim wherein the bile salt is underivatised or derivatised.

9. The amide according to claim 8 wherein the underivatised bile salt is selected from cholate, deoxycholate, chenodeoxycholate and ursodeoxycholate.

10. The amide according to claim 9 wherein the bile salt is cholate.

11. An amide according to claim 8 wherein the derivatised bile salt is selected from taurocholate, taurodeoxycholate, tauroursodeoxycholate, taurochenodeoxycholate, glycholate, glycodeoxycholate, glycoursodeoxycholate, glycochenodeoxycholate, tauroolithocholate and glycolithocholate.

12. An amide according to any previous claim wherein the peptide is selected from insulin, secretin, gastrin, gastrin releasing peptide, glucagon, cholecystokinin (CCK) gastric inhibitory peptide (also known as glucose

insulinotropic peptide (GIP)), parathyroid hormone, thyrotropin-releasing hormone, gonadotropin-releasing hormone (also known as lutenizing hormone releasing hormone (LHRH)), corticotropin-releasing hormone, somatostatin, adrencorticotropic hormone (ACTH), renin, angiotensin I, angiotensin II, atrial natriuretic hormone (ANH), somatomedins, calcitonin, haemoglobin, cytochrome C, horseradish peroxidase, aprotinin, muchroom tyrosinase, erythropoietin, somatotropin (growth hormone), growth hormone releasing hormone, galanin, urokinase, Factor IX (also known as Christmas factor), tissue plasminogen activator, antibodies superoxide dismutase, catalase, peroxidase, ferritin, interferon, Factor VIII, soy bean trypsin inhibitor, GLP1, blood coagulation factors, somatostatin, antidiuretic hormone (ADH), oxytocin, polysaccharides, hirudin, and glycoproteins, such as follicle stimulating hormone (FSH), lutenizing hormone (LH) inhibin, chorionic gonadotropin (CGT) and thyroid stimulating hormone (TSH), and analogues and fragments of all these, or mixtures of one or more of these.

13. An amide according to claim 12 wherein the somatomedins are selected from IGF1 and IGF2.

14. An amide according to claim 12 wherein the antibodies are selected from IgG, IgM, IgA, IgD, IgE.

15. A pharmaceutical formulation, comprising an amide according to any preceding claim and a pharmaceutically acceptable carrier.

16. A pharmaceutical formulation according to claim 15 wherein the formulation is formulated to be administered orally.


17. A pharmaceutical formulation according to claim 16 wherein said formulation is encapsulated to prevent formulation degradation in the stomach.

18. An amide according to any one of claims 1-14 or a physiologically functional derivative thereof, for use in therapy.

19. A method for the preparation of a pharmaceutical formulation comprising bringing into association an amide according to any one of claims 1-14 and a pharmaceutically acceptable carrier therefor.

20. Use of an amide according to any one of claims 1-14 in the manufacture of a medicament in a form suitable for oral administration.

21. Use of a compound according to Formula (III):



(III)

wherein R^1 to R^5 are independently selected from OH, H or C_{1-6} alkyl; and
B is $-R^6-CO-Z$

wherein R^6 is C_2 to C_6 branched or linear alkylene; and
Z is a pharmaceutically active agent;

in the manufacture of a medicament suitable for parenteral administration.

22. Use according to claim 21 wherein Z is bound to the bile acid/salt by an amide linkage.

23. Use according to claim 21 or claim 22 wherein said pharmaceutical agent is selected from polypeptides and glycoproteins, polysaccharides, oligonucleotides/polynucleotides, anaesthetics, anxiolytics, hypnotics, neuroleptics, anti-depressants, anti-epileptics, anti-Parkinsonian drugs, opioid analgesics, neuropeptide transmitters, neuropeptide transmitter antagonists, muscarinic agonists, anti-cholinesterases, muscarinic antagonists, nicotinic antagonists, direct sympathomimetics, indirect sympathomimetics, adrenergic blocking drugs, adrenoceptor antagonists, vasodilators, anti-angina drugs, cardiostonic drugs, anti-dysrhythmic drugs, anti-coagulants, plasma lipid lowering drugs, anti-anaemia drugs, anti-inflammatory drugs, diuretics, histamine antagonists, anti-peptic ulcer drugs, anti-gut motility disorder drugs, chemotherapy drugs, anti-bacterial drugs, anti-viral drugs, anti-fungal drugs and anti-parasite drugs.

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 February 2001 (08.02.2001)

PCT

(10) International Publication Number
WO 01/09163 A3

- (51) International Patent Classification⁷: **C07K 14/595**, 14/575, 14/47, A61K 47/48, 38/04
- (21) International Application Number: PCT/GB00/02903
- (22) International Filing Date: 28 July 2000 (28.07.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
9917793.3 30 July 1999 (30.07.1999) GB
- (71) Applicant (for all designated States except US): **THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW** [GB/GB]; Gilbert Scott Building, University Avenue, Glasgow G12 8QQ (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **MORRISON, James, Duncan** [GB/GB]; West Medical Building, University of Glasgow, University Avenue, Glasgow G12 8QQ (GB). **LUCAS, Michael, Leslie** [GB/GB]; West Medical Building, University of Glasgow, University Avenue, Glasgow G12 8QQ (GB). **WHEELER, Sarah** [GB/GB]; West Medical Building, University of Glasgow, University Avenue, Glasgow G12 8QQ (GB).
- (74) Agents: **MCCALLUM, William, Potter et al.**; Cruikshank & Fairweather, 19 Royal Exchange Square, Glasgow G1 3AE (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- (88) Date of publication of the international search report:
7 September 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: IMPROVEMENT OF PEPTIDE TRANSPORT BY CONJUGATION WITH BILE ACIDS

(57) Abstract: The present invention relates to improving and/or increasing the bioavailability of a biologically active substance, such as a peptide. In particular the present invention relates to the conjugation of the biologically active substance to a bile acid. The conjugated biologically active substance is suitable particularly for oral or parental administration.

WO 01/09163 A3

4

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Attorney Docket No. 9013-46

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled, **PEPTIDE TRANSPORT**,

the specification of which

☐ is attached hereto

OR

☒ was filed on filed on **July 28, 2000** as PCT International Application Number **PCT/GB00/02903**

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

| | | | |
|-----------|---------|------------------|---|
| 9917793.3 | GB | 07/30/1999 | <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No |
| Number | Country | MM/DD/YYYY Filed | Priority Claimed |

| | | | |
|--------|---------|------------------|--|
| | | | <input type="checkbox"/> Yes <input type="checkbox"/> No |
| Number | Country | MM/DD/YYYY Filed | Priority Claimed |

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

| | |
|-----------------------|--------------------------|
| None | |
| Application Number(s) | Filing Date (MM/DD/YYYY) |

| | |
|-----------------------|--------------------------|
| | |
| Application Number(s) | Filing Date (MM/DD/YYYY) |

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application (37 C.F.R. § 1.63(d)).

| | | |
|-------------------|-------------|--------------------------------------|
| PCT/GB00/02903 | 07/28/2000 | Published |
| Appln. Serial No. | Filing Date | Status Patented/Pending/Abandoned |

| | | |
|-------------------|-------------|--------------------------------------|
| | | |
| Appln. Serial No. | Filing Date | Status Patented/Pending/Abandoned |

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

[illegible]

The following table shows the results of the regression analysis for the dependent variable "Number of children in the household" (N = 1,000). The independent variables are "Age of the head of household" and "Gender of the head of household". The results are presented in the following table:

| Variable | Coefficient | Standard Error | t-statistic | p-value |
|---------------------------------|-------------|----------------|-------------|---------|
| Age of the head of household | 0.001 | 0.001 | 1.00 | 0.316 |
| Gender of the head of household | 0.001 | 0.001 | 1.00 | 0.316 |
| Constant | 1.000 | 0.000 | 1.00 | 0.316 |

The results show that the coefficient for "Age of the head of household" is 0.001, with a standard error of 0.001 and a t-statistic of 1.00. The p-value is 0.316, which is greater than the 0.05 level of significance. Therefore, we fail to reject the null hypothesis that the coefficient is zero.

The coefficient for "Gender of the head of household" is also 0.001, with a standard error of 0.001 and a t-statistic of 1.00. The p-value is 0.316, which is greater than the 0.05 level of significance. Therefore, we fail to reject the null hypothesis that the coefficient is zero.

The constant term is 1.000, with a standard error of 0.000 and a t-statistic of 1.00. The p-value is 0.316, which is greater than the 0.05 level of significance. Therefore, we fail to reject the null hypothesis that the constant is zero.

20792

PATENT TRADEMARK OFFICE

F. Michael Sajovec
Myers Bigel Sibley & Sajovec
Post Office Box 37428
Raleigh, NC 27627

F. Michael Sajovec
(919)854-1400

(919) 854-1401

1-00

Signature:

J. Morrison
United States

Date: 15th April 2002

United Kingdom

Great Britain

West Medical Building
University of Glasgow
University Avenue
Glasgow G12 8QQ United Kingdom

GBX

